Veeva Systems(NYSE) VEEV

Veeva Systems Inc. makes cloud software specifically for the life sciences industry. Its tools help drug and medical device companies manage clinical trials and product sales. These solutions help life sciences firms work faster and follow government rules.

Software for Every Stage

• R&D and Quality Solutions: Cloud applications that manage clinical trials, regulatory compliance, and quality control; represented 55% of total revenue for the fiscal year ended Jan. 31, 2026.
• Commercial Solutions: Software and data tools for sales, marketing, and patient engagement; accounted for 45% of total revenue for the fiscal year ended Jan. 31, 2026.
• Subscription Services: Ongoing access to software and data solutions for life sciences companies; comprised 83% of total revenue for the six months ended July 31, 2026.
• Professional Services: Consulting and training to help customers set up and use software; made up 17% of total revenue for the six months ended July 31, 2026.

Strategic Growth Moves

• Acquired Rise Healthcare Tech, Inc. (Ostro) during the six months ended July 31, 2026.
• Authorized a $2 billion share repurchase program in Jan. 2026 to buy back outstanding common stock.
• Repurchased and retired 2.7 million shares for approximately $467 million during the six-month period ended July 31, 2026.
• Expanded product offerings to serve industries beyond life sciences in North America and Europe.

What Makes Veeva Different?

Veeva offers its specialized research and quality tools to industries outside the life sciences sector in North America and Europe. Its global operations span a network across North America, Europe, and the Asia Pacific region.

A Look at the Numbers

• Total revenue reached $3.2 billion in the fiscal year ended Jan. 31, 2026, up 16% year over year.
• Subscription revenue grew 17% year over year to $2.7 billion during the fiscal year ended Jan. 31, 2026.
• Net income was $909 million in the fiscal year ended Jan. 31, 2026, compared to $714 million in the prior fiscal year.
• The company served 1,552 customers as of Jan. 31, 2026, an increase from 1,477 customers the previous year.
• Cash, cash equivalents, and short-term investments totaled $7.2 billion as of July 31, 2026.

Bottom Line

Veeva has evolved from a niche provider into a comprehensive cloud platform for the global life sciences industry. Its shift toward research and development solutions has successfully diversified the business beyond its original focus on sales tools.